Glyburide Suppresses Inflammation-Related Colorectal Tumorigenesis Through Inhibition of NLRP3 Inflammasome
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.NLRP3 inflammasome inhibition, not deficiency, suppressed colitis-associated colorectal cancer in mice. Glyburide, an NLRP3 inhibitor, reduced tumors and inflammation, showing promise for cancer prevention.
Area Of Science
- Gastroenterology
- Oncology
- Immunology
Background
- Colorectal cancer (CRC) is a severe complication of inflammatory bowel disease (IBD).
- The NLRP3 inflammasome is implicated in IBD pathogenesis and CRC development.
- Targeting NLRP3 inflammasome may offer therapeutic strategies for IBD-related CRC.
Purpose Of The Study
- To investigate the role of NLRP3 inflammasome in colitis and CRC.
- To evaluate the effects of NLRP3 deficiency and glyburide (an NLRP3 inhibitor) on colitis and colitis-associated CRC.
Main Methods
- Utilized mouse models for acute colitis and azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis.
- Compared control mice with NLRP3-deficient mice and mice treated with glyburide.
- Assessed colonic inflammation, tumor development, and inflammatory cytokine gene expression.
Main Results
- NLRP3 deficiency exacerbated acute colitis, while glyburide treatment did not.
- Both NLRP3 deficiency and glyburide treatment reduced colorectal tumor formation.
- Reduced inflammatory cytokine gene expression was observed in NLRP3-deficient and glyburide-treated mice.
Conclusions
- NLRP3 deficiency exacerbates acute colitis but suppresses colitis-related colorectal tumorigenesis.
- Pharmacological inhibition of NLRP3 by glyburide suppresses colitis-related tumorigenesis by reducing chronic inflammation.
- Glyburide demonstrates potential as a chemopreventive agent for colitis-associated colorectal cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...